CLINICAL_TRIALS
trial_result
· 2026-03-10
Clinical Trial Update: Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma [Phase 2]
Summary
The Phase 2 study of pixantrone in CD20+ relapsed/refractory aggressive non-Hodgkin lymphoma has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: The Lymphoma Academic Research Organisation | Conditions: Aggressive Non-Hodgkin Lymphoma | Phase 2 | Status: COMPLETED